Forum Leadership

The Forum Advisory Board includes:

  • Debbie Benjamin, Director of Facilities & Lab Management, Celgene
  • Nils Bergenhem, Principal, NB R&D Consulting
  • Bob Bondaryk, President and CEO, KeraFast
  • Susan Boynton, VP, Global Regulatory Affairs, Shire HGT
  • Kathy Call,Senior Director & Head, Proteogenomics, Genzyme Corporation
  • Dalia Cohen, Founder & President/Science Entrepreneur, ALN Associates
  • Michael G. Donovan, Partner and Northeast Area Industry Leader for Biotechnology, Ernst & Young
  • Brian Fenton, Executive Director, Business Development, Shire HGT
  • Roger Frechette, Co-Founder and Principal, New England Pharm Associates
  • George Hillman, Business Development, Bach Pharma
  • Jim Holmes, Partner, Deloitte
  • Joanne Kamens, Executive Director, Addgene
  • Ralph Lambalot, VP, Biologics Development & Manufacturing Launch, AbbVie
  • Tsvetelina Lazarova, Co-Founder & Co-Owner, MedChem Partners
  • Larry Wittenberg, Co-Chair of Life Sciences Practice, Goodwin Proctor

Working Group Co-Chairs include:

Biostatistics / Data Management / Clinical Trials

  • Kevin Anderson, Associate Director, Global Clinical Operations, Alexion Therapeutics
  • John Balser, President, Veristat
  • Michelle Harrison, Assicuate Director, Clinical Data Management, Vertex Pharmaceuticals 
  • Sarah Tuller, Director, Regulatory Drugs/Biologics, Voisin Consulting Life Sciences
  • Joanne Schindler, Vice President, Clinical Development, SynDevRx, Inc.

Business Development & Finance

  • John P. Reilly, VP Business Development, Tetragenetics, Inc.
  • Maude Tessier, Merck Research Laboratories, Director, Search & Evaluation, Business Development and Licensing, Boston Innovation Hub
  • Paul Thibodeau, Senior Director of Global Business Development, TEVA Pharmaceuticals
  • Helen Ho, Director, Business Development & Operations, Agios Pharmaceuticals
  • Edwine Michel, Senior Manager, Economic Evaluation, Corporate Strategy & Business Development, Sanofi S.A.
  • Josh Mandel-Brehm, Associate Director, Business Develoment and M&A, Biogen Idec, Inc.


  • Peter Meltzer, President & CEO, Organix, Inc.
  • Bhavishya Mittal, Senior Scientist I, Formulation Sciences, PTRDL, Millennium: The Takeda Oncology Company
  • Ed Price, President, PCI Synthesis
  • Raj Rajur, Chairman & CEO, CreaGen Biosciences, Inc.
  • Holly Collette, Technical Product Specialist, Research Model Services, Charles River Laboratories
  • Nicolette Miranda, Senior Associate Project management, Novartis Institute for Biomedical Research Inc.

Drug Discovery

  • Masha Hareli, Founder & President, ATR, LLC
  • Steve Riesinger, Co-founder, MedChem Partners
  • Robert Suto, President and CSO, Xtal Biostructures Inc. 

Entrepreneur's University

  • Steve Alteiri, Associate, Bingham McCutchen LLP
  • Marc Cote, Co-founder & COO, Accellient Partners, LLC
  • John Hession, Partner, Cooley LLP
  • Luba Greenwood, VP Business Development, Pronutria, Inc.

Formulation and Drug Delivery

  • Shikha P. Barman, Ph.D., CEO and CTO, Integral BioSystems
  • Angelos Dovletoglou, Executive Director of Preclinical Development Sciences, Epizyme
  • Alex Nivorozhkin, Co-Founder & COO, Neo-Advent
  • Craig Dunbar, VP of Product Development, Blend Therapeutics, Inc.

Human Resources

  • Patrick Marshall, Chief Business Officer/Co-Founder, StratAcuity
  • James Richardson, Client Executive, William Gallagher Associates
  • Hewan Small, Senior Director, Human Resources, Novartis Institute for Biomedical Research, Inc.
  • Wendy Durkin, Regional Business Development Manager, Foundation Medicine, Inc.
  • Lee Merrill, VP, Human Resources, Forma Therapeutics

Legal & Regulatory

  • Mladen Bozic, Director, Global Regulatory Policy & Intelligence, Shire
  • David Hoffman, Senior Counsel, Sunovion Pharmaceuticals, Inc.
  • Konstantin Linnik, Partner, Lawyer, Nutter McClennen & Fish LLP
  • Jayati Vaidya, Senior Consultant, Advisory Services, Deloitte & Touche LLP
  • David Mantus, Associate Professor, Director of MS Program in Regulatory Affairs & Health Policy, MCPHS University
  • Lana Gladstein, Partner, Intellectual Property Litigation & Strategy, Pepper Hamilton LLP
  • Sarah Tuller, Director, Regulatory Drugs/Biologics, Voisin Consulting Life Sciences

 Marketing & Communications

  • Rob Goldstein, VP, Communications & Public Affairs, ALS Therapy Development Institute
  • Mike Walsh, Director of Advocacy Engagement, InterMune, Inc.
  • David Altman, Marketing and Communications Specialist, Boston Children's Hospital
  • Jim Baker, Executive Director, Corporate Affairs, Idera Pharmaceuticals

Safety, Environmental and Facility Operations

  • Dick Aichelmann, Associate Director EH&S, Ironwood Pharmaceuticals
  • Denise Aronson, President, Safety Partners
  • Susan Smits, VP of Operations, Mabbett & Associates, Inc.

About MassBio

MassBio is a not-for-profit organization committed to advancing the development of critical new science, technology and medicines that benefit people worldwide.

Founded in 1985, MassBio represents over 600 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and health care, and works to advance policy and promote education, while providing member programs and events, industry information, and services.

image of rss iconLatest Updates